Latif, Anne-Louise
Newcombe, Ashley
Li, Sha http://orcid.org/0000-0002-1006-1785
Gilroy, Kathryn
Robertson, Neil A. http://orcid.org/0000-0002-9509-1157
Lei, Xue
Stewart, Helen J. S. http://orcid.org/0000-0001-8267-8373
Cole, John
Terradas, Maria Terradas http://orcid.org/0000-0002-3823-8968
Rishi, Loveena
McGarry, Lynn http://orcid.org/0000-0002-7055-2615
McKeeve, Claire
Reid, Claire
Clark, William
Campos, Joana
Kirschner, Kristina http://orcid.org/0000-0001-7607-8670
Davis, Andrew
Lopez, Jonathan
Sakamaki, Jun-ichi
Morton, Jennifer P. http://orcid.org/0000-0001-5766-9141
Ryan, Kevin M.
Tait, Stephen W. G. http://orcid.org/0000-0001-7697-132X
Abraham, Sheela A. http://orcid.org/0000-0003-4114-138X
Holyoake, Tessa
Higgins, Brian
Huang, Xu http://orcid.org/0000-0001-6706-199X
Blyth, Karen http://orcid.org/0000-0002-9304-439X
Copland, Mhairi http://orcid.org/0000-0002-7655-016X
Chevassut, Timothy J. T. http://orcid.org/0000-0001-8672-1906
Keeshan, Karen http://orcid.org/0000-0001-7266-0890
Adams, Peter D. http://orcid.org/0000-0002-0684-1770
Funding for this research was provided by:
Cancer Research UK (C10652/A16566)
Article History
Received: 18 October 2019
Accepted: 25 November 2020
First Online: 11 January 2021
Competing interests
: M.C. is Chief Investigator of an investigator-led clinical trial (EudraCT number 2018-001843-29) funded by CR-UK (grant number A24896: CRUK/17/016) using idasanutlin (RG7388) in chronic myeloid leukemia. The remaining authors declare no competing interests.